AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2710
-0.0189 (-6.52%)
At close: May 13, 2026, 4:00 PM EDT
0.2700
-0.0010 (-0.37%)
After-hours: May 13, 2026, 8:00 PM EDT
AIM ImmunoTech Employees
As of December 31, 2025, AIM ImmunoTech had 21 total employees, including 19 full-time and 2 part-time employees. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
$4,190
Profits / Employee
-$664,667
Market Cap
2.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -2 | -8.70% | 19 | 2 |
| Dec 31, 2024 | 23 | -5 | -17.86% | 21 | 2 |
| Dec 31, 2023 | 28 | 4 | 16.67% | 26 | 2 |
| Dec 31, 2022 | 24 | 1 | 4.35% | 22 | 2 |
| Dec 31, 2021 | 23 | 0 | - | 21 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Silexion Therapeutics | 14 |
| Biodexa Pharmaceuticals | 11 |
| Decoy Therapeutics | 11 |
| Ensysce Biosciences | 10 |
| Artelo Biosciences | 7 |
| Adial Pharmaceuticals | 5 |
AIM News
- 5 days ago - AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds - GlobeNewsWire
- 6 days ago - AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential - GlobeNewsWire
- 27 days ago - AIM ImmunoTech Transcript: Virtual Investor Closing Bell - Transcripts
- 27 days ago - AIM ImmunoTech highlights accelerating momentum in pancreatic cancer program - TheFly
- 4 weeks ago - AIM ImmunoTech Provides Routine Update on Annual Filings - GlobeNewsWire
- 7 weeks ago - Biotech Alert: Searches spiking for these stocks today - TheFly
- 2 months ago - Why Is AIM ImmunoTech Stock (AIM) Up Today? - TipRanks
- 2 months ago - AIM announces approval of patent for Ampligen in Japan - TheFly